BioNTech (NASDAQ:BNTX) Trading Down 3.3% – Here’s Why

Shares of BioNTech SE (NASDAQ:BNTX) dropped 3.3% during mid-day trading on Friday . The stock traded as low as $108.75 and last traded at $110.66. Approximately 741,146 shares were traded during trading, a decline of 6% from the average daily volume of 786,373 shares. The stock had previously closed at $114.47.

Analyst Ratings Changes

BNTX has been the topic of several research reports. HSBC lifted their price objective on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and lifted their price target for the stock from $91.00 to $125.00 in a report on Monday, September 16th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. HC Wainwright lifted their price target on shares of BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Finally, UBS Group lifted their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Five analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $131.92.

BioNTech Stock Down 2.4 %

The stock has a market capitalization of $26.57 billion, a PE ratio of 223.54 and a beta of 0.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The business’s fifty day moving average price is $104.56 and its two-hundred day moving average price is $94.20.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The business had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company’s revenue for the quarter was down 23.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.86) earnings per share. On average, equities research analysts forecast that BioNTech SE will post -3.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its position in BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after purchasing an additional 111 shares during the period. Covestor Ltd raised its position in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares during the period. Midwest Professional Planners LTD. raised its position in shares of BioNTech by 7.2% in the first quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock worth $293,000 after acquiring an additional 212 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of BioNTech by 2.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock worth $904,000 after acquiring an additional 223 shares during the period. Finally, EverSource Wealth Advisors LLC raised its position in shares of BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.